Core Viewpoint - The Harbin International Economic and Trade Fair showcases the continuous improvement and innovation of Harbin Pharmaceutical Group, emphasizing its commitment to providing high-quality products for public health [1][2]. Group 1: Product Offerings - Harbin Pharmaceutical Group presents a diverse range of products at the fair, including pharmaceuticals, health foods, general foods, beauty and personal care items, medical devices, daily chemical products, and cultural creative products [2]. - The company features brand zones for its various product lines, such as "San Jing" series, "Shi Yi Tang" traditional Chinese medicine products, "Ha Yao Liu" series, "GNC" health products, and "Ha Yao Biotech" high-end beauty products [2]. Group 2: Research and Development - The company has established a solid research and development framework, recently obtaining approval for a solid preparation pilot platform and successfully passing the consistency evaluation for a generic drug [3]. - Harbin Pharmaceutical Group focuses on developing both traditional Chinese medicine and biological products, enhancing its diverse R&D capabilities [5]. Group 3: Production and Management - The company is implementing lean management practices to reduce costs and enhance product quality while strengthening its industrial chain [4]. - Harbin Pharmaceutical Group emphasizes maintaining product quality as its top priority and leveraging its group advantages for operational efficiency [4]. Group 4: Marketing and Community Engagement - The company is actively expanding its market presence through high-quality products and services, launching brand activities like the "San Jing Blue Bottle Growth Season" [5]. - Harbin Pharmaceutical Group has also contributed to local tourism by opening the "Harbin Art Palace Print Museum," which has attracted over 2.67 million visitors since its opening [5]. Group 5: Future Directions - The company aims to enhance its core competitiveness by focusing on system construction, control optimization, product development, technological innovation, marketing breakthroughs, talent cultivation, and brand strategy [6]. - Harbin Pharmaceutical Group is committed to fulfilling its social responsibilities and contributing to the high-quality development of the Heilongjiang region [6].

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]

每经记者｜陈晴 每经编辑｜张海妮 并购重组 哈药股份：三精制药拟以2344.6万元收购三精千鹤42.82%股权 湖北宜化：控股股东宜化集团拟以2亿元~4亿元增持 新疆火炬公告称，公司拟以1.25亿元收购江西中久天然气集团有限公司持有的玉山县利泰天然气有限公 司100%股权。本次交易构成关联交易，未构成重大资产重组。 回购增持 荣信文化：拟以2000万元~2200万元回购股份 荣信文化公告称，公司拟使用自有资金及回购专项贷款资金，以集中竞价交易的方式进行股份回购，回 购金额不低于2000万元（含）且不超过2200万元（含），回购价格不超过37元/股。 湖北宜化公告，控股股东宜化集团计划自2025年5月19日起的6个月内，通过深交所交易系统增持公司股 份，增持金额不低于2亿元且不超过4亿元。本次增持不设置价格区间。 风险事项 富创精密：两股东拟合计减持不超4%股份 哈药股份公告，公司全资子公司哈药集团三精制药有限公司拟收购三名自然人所持有的哈药集团三精千 鹤制药有限公司42.82%的股权，收购金额为2344.6万元。 新疆火炬：拟1.25亿元收购玉山利泰100%股权 威孚高科：拟以1亿元~1.5亿元回购股份 威孚 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-019 哈药集团股份有限公司 关于公司全资子公司收购股权的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?投资标的名称：哈药集团股份有限公司（以下简称"公司"）全资 子公司哈药集团三精制药有限公司（以下简称"三精制药"）拟收购三名 自然人所持有的哈药集团三精千鹤制药有限公司（以下简称"标的公司" 或"三精千鹤"）42.82%的股权。收购后，三精千鹤成为三精制药的全资 子公司。 ?投资金额：本次投资金额为 2,344.60 万元人民币，资金来源于三精 制药自有资金。 ?相关风险提示： 署正式协议、交易能否最终完成尚存在不确定性。 近日，三精千鹤自然人股东就三精千鹤股权有关事宜提起诉讼。根据 人民法院调解方案，公司同意三精制药以 2,344.60 万元受让刘彦铎等三名 自然人所持有的三精千鹤 42.82%的股权。公司全资子公司三精制药持有三 精千鹤 57.18%的股权，本次股权转让完成后，三精制药将持有三精千鹤 公司于 2025 年 5 月 15 ...

公司全资子公司哈药集团三精制药有限公司（以下简称"三精制药"） 原持有哈药集团三精千鹤制药有限公司（以下简称"三精千鹤"）57.18% 的股权，董事会同意三精制药以2,344.60万元受让自然人持有的三精千鹤 将有利于优化资源配置、深化业务协同，进一步增强业务板块的市场竞争 力。公司董事会授权管理层具体办理本次对外投资相关事宜。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披 露的《哈药集团股份有限公司关于公司全资子公司收购股权的公告》（公 告编号：2025-019）。 证券代码:600664 证券简称:哈药股份 编号:临 2025-018 哈药集团股份有限公司 十届十四次董事会决议公告 本公 司董事 会及全 体董 事保证 公告内 容不存 在任何 虚假记 载、 误导性 陈述或 者重大 遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第十届董事会第十四次 会议以书面方式发出通知，于 2025 年 5 月 15 日以现场结合通讯形式召开。 会议应参加董事 9 人，实际参加董事 9 人，会议召开符合《中华人民共和 国公司法》和《公司章程》 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-020 交易简要内容：哈药集团股份有限公司（以下简称"公司"）拟通 过挂牌出租的方式对位于哈尔滨市道外区南直路 326 号的分公司哈药集 团制药六厂（以下简称"哈药六厂"）部分闲置厂房进行资产盘活。 根据《上海证券交易所股票上市规则》《上市公司重大资产重组管 理办法》，上述事项无须提交股东大会审议，也不构成关联交易和重大 资产重组。 相关风险提示：受政策、市场环境变化等因素影响，本次闲置资产 盘活方案在交易对方、交易价格及实施进度等方面仍存在不确定性，敬 请投资者理性决策，注意防范投资风险。 一、交易概述 为盘活存量闲置资产，提高资产使用效率，公司对位于哈尔滨市道 外区南直路 326 号的哈药六厂闲置厂房制定了综合规划方案，根据规划 方案，公司拟通过挂牌出租的方式对部分闲置厂房进行资产盘活。 公司于 2025 年 5 月 15 日召开第十届董事会第十四次会议，审议通 过了《关于公司分公司挂牌出租部分闲置资产的议案》，董事会同意对 分公司哈药六厂南直路部分闲置厂区及房产整体挂牌出租，授权公司管 理层开展后续挂牌以及合同签订等事项。本次授权决议的有效 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-019 哈药集团股份有限公司 关于公司全资子公司收购股权的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：哈药集团股份有限公司（以下简称"公司"）全资 子公司哈药集团三精制药有限公司（以下简称"三精制药"）拟收购三名 自然人所持有的哈药集团三精千鹤制药有限公司（以下简称"标的公司" 或"三精千鹤"）42.82%的股权。收购后，三精千鹤成为三精制药的全资 子公司。 投资金额：本次投资金额为 2,344.60 万元人民币，资金来源于三精 制药自有资金。 相关风险提示： 1、本次拟对外投资事项涉及的相关正式协议尚未签署，后续是否能签 署正式协议、交易能否最终完成尚存在不确定性。 2、本次股权收购实施后，标的公司是否能够高效、顺利运营并达成预 期目标存在一定的不确定性，可能面临行业、政策、市场环境变化及经营 管理等风险,投资收益存在不确定性，敬请投资者注意投资风险。 一、对外投资概述 近日，三精千鹤自然人股东就三精千鹤股权有关事宜提起诉讼 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-018 二、《关于公司分公司挂牌出租部分闲置资产的议案》（同意9票，反 对0票，弃权0票） 为了盘活公司资产，提高资产使用效率，根据房地产市场环境变化情 况，适时调整公司闲置资产处置策略，董事会同意对公司分公司哈药六厂 南直路部分闲置厂区及房产整体挂牌出租，授权公司管理层开展后续挂牌 哈药集团股份有限公司 十届十四次董事会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第十届董事会第十四次 会议以书面方式发出通知，于 2025 年 5 月 15 日以现场结合通讯形式召开。 会议应参加董事 9 人，实际参加董事 9 人，会议召开符合《中华人民共和 国公司法》和《公司章程》的有关规定，会议审议了如下议案： 一、《关于公司全资子公司收购股权的议案》（同意 9 票，反对 0 票，弃权 0 票） 公司全资子公司哈药集团三精制药有限公司（以下简称"三精制药"） 原持有哈药集团三精千鹤制药有限公司（以下简称"三精千鹤"）57.18 ...

哈药股份（600664）公告，公司全资子公司哈药集团三精制药有限公司拟收购三名自然人所持有的哈药 集团三精千鹤制药有限公司42.82%的股权，收购金额为2344.6万元人民币。收购完成后，三精千鹤将成 为三精制药的全资子公司。三精千鹤2024年营业收入5502.89万元，净利润39.07万元。 ...

Group 1: Company Overview - The company has seen significant revenue growth and steady profit improvement in its GNC China business, but there is still room for optimization in expense management [1] - The company plans to actively explore the potential of commercial contract promotion and implement various measures to reduce costs and improve efficiency, focusing on precise allocation of sales expenses [1] - The company aims to strengthen brand value and promote compliant, high-quality development of its GNC China business while closely monitoring market dynamics [1] Group 2: Market and Product Development - The orthopedic external patch market in China has exceeded 10 billion, with a compound annual growth rate of 9.55% driven by aging population and chronic disease management awareness [2] - The company is focusing on the development of traditional Chinese medicine combined with modern transdermal technology for its key prescription product, the wind-dispelling pain gel [2] - The company plans to continue digital and intelligent transformation of its traditional Chinese medicine production lines to enhance efficiency and responsiveness to national policy [2] Group 3: Future Product Pipeline - The company has received approval for a generic drug, lactulose oral solution, and is progressing with two other products through consistency evaluation [2] - Upcoming products expected to be approved in the next two years include oseltamivir phosphate dry suspension and iron protein succinate oral solution, among others [2] - The company will focus on major disease areas such as cardiovascular, digestive metabolism, respiratory, anti-infection, and anti-tumor, with an emphasis on developing medications for the elderly and children [2] Group 4: Financial Management - The company disclosed that its interest income comes solely from bank deposits, with no involvement in financial products or lending for interest income [3] - The company emphasizes a scientific and reasonable financial planning approach to maintain sufficient debt repayment capacity and a reasonable capital structure [3] - The company has established a budget management system to ensure that every expense has a responsible party and approval process, with regular evaluations and adjustments [3][4]